A case series of drotrecogin alfa (activated) in lung transplant recipients.
A case series of drotrecogin alfa (activated) in lung transplant recipients.
复制标题
肺移植受者中的 drotrecogin alfa（激活）病例系列。
DOI：
10.1097/01.tp.0000226077.87011.87
复制
发表时间：
2006
期刊：
影响因子：
6.2
通讯作者：
Milstone,AaronP
中科院分区：
文献类型：
--
作者：
Daniels,TitusL;Dummer,JStephen;Bernard,GordonR;Milstone,AaronP
肺移植受者的严重脓毒症是一个具有挑战性的问题，具有很高的死亡率。重组人活化蛋白C(drotrecogin alfa[激活])已被批准用于严重脓毒症患者。它的使用已被证明是安全的，并提供了生存优势。然而，在肺移植受者中，激活的屈曲霉素阿尔法的安全性还没有得到评估。我们首次报告了在6例肺移植受者中使用屈曲霉素α的情况。临床试验是有必要的，以进一步评估在移植受者中激活的屈曲霉金α的使用。
Severe sepsis in lung transplant recipients is a challenging problem and carries a high mortality. Recombinant human activated protein C (drotrecogin alfa [activated]) has been approved for use in patients with severe sepsis. Its use has been shown to be safe and impart a survival advantage. However, the safety of drotrecogin alfa activated has not been evaluated in lung transplant recipients. We report for the first time on the use of drotrecogin alfa activated in six lung transplant recipients. Clinical trials are warranted to further evaluate the use of drotrecogin alfa activated in transplant recipients.